Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

Data ReadoutpositiveTEV-'749Positive

AI Analysis

Summary

Teva announced positive post hoc data from the SOLARIS Phase 3 trial of TEV-'749 (olanzapine LAI), a once-monthly subcutaneous injectable for schizophrenia, demonstrating high stabilization rates and long-term efficacy. The findings were presented at Psych Congress in New Orleans.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Post hoc data from SOLARIS Phase 3 trial highlighted high rates of stabilization and long-term efficacy and safety

Importance:6/10

Sentiment:

0.60

schizophrenialong-acting injectableolanzapinePhase 3data presentationefficacysafety

Related Companies

$TEVA

Read the original article

Published by GlobeNewswire Pharma on September 18, 2026 8:30 PM

Read Original